Bioavailability of iron multi-amino acid chelate preparation in mice and human duodenal HuTu 80 cells by Kajarabille, Naroa et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1017/S0007114517000186
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Kajarabille, N., Brown, C., Cucliciu, A., Thapaliya, G., & Latunde-Dada, G. O. (2017). Bioavailability of iron multi-
amino acid chelate preparation in mice and human duodenal HuTu 80 cells. British Journal of Nutrition, 117(6),
767-774. https://doi.org/10.1017/S0007114517000186
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
Bioavailability of iron multi-amino acid chelate preparation in mice and human
duodenal HuTu 80 cells
Naroa Kajarabille†, Catriona Brown, Anamaria Cucliciu, Gita Thapaliya and Gladys O. Latunde-Dada*
Diabetes and Nutritional Sciences Division, Faculty of Life Sciences and Medicine, King’s College London, Franklin Wilkins
Building, 150 Stamford Street, London SE1 9NH, London, UK
(Submitted 20 September 2016 – Final revision received 5 January 2017 – Accepted 6 January 2017)
Abstract
Strategies for preventing Fe deﬁciency include Fe supplementation and Fe fortiﬁcation of foods. The absorption, metabolism and chemical
characteristics of Fe multi-amino acid chelate (IMAAC) are not known. Absorption of IMAAC was compared with FeSO4 in Fe-depleted mice
and in vitro chemical studies of the Fe supplement was performed in HuTu 80 cells. Hb repletion study was carried out in Fe-deﬁcient CD1
mice that were fed for 10 d a diet supplemented with ferrous IMAAC or FeSO4. A control group of Fe-replete mice was fed a diet with adequate
Fe concentrations throughout the study. Tissues were collected from the mice, and the expression of Fe-related genes was determined by
quantitative PCR. Ferric reductase and Fe uptake were evaluated in HuTu 80 cells. Supplementation of the diet with FeSO4 or IMAAC
signiﬁcantly increased Hb levels (P< 0·001) in Fe-deﬁcient mice from initial 93·9 (SD 10·8) or 116·2 (SD 9·1) to 191 (SD 0·7) or 200 (SD 0·5) g/l,
respectively. Initial and ﬁnal Hb for the Fe-deﬁcient control group were 87·4 (SD 6·7) and 111 (SD 11·7) g/l, respectively. Furthermore, the liver
non-haem Fe of both supplement groups increased signiﬁcantly (P< 0·001). IMAAC was more effective at restoring Fe in the spleen compared
with FeSO4 (P< 0·005). Gene expression showed the IMAAC supplement absorption is regulated by the body’s Fe status as it signiﬁcantly up-
regulated hepcidin (P< 0·001) and down-regulated duodenal cytochrome b mRNA (P< 0·005), similar to the effects seen with FeSO4. A
signiﬁcant proportion of Fe in IMAAC is reduced by ascorbic acid. Fe absorption in mice and cells was similar for both IMAAC and FeSO4 and
both compounds induce and regulate Fe metabolism genes similarly in the maintenance of homeostasis in mice.
Key words: Bioavailability: Iron: Cells: Mice
Fe deﬁciency anaemia (IDA) is a nutritional disorder afﬂicting
large population groups in the world(1). It is prevalent amongst
vulnerable infants, adolescent girls, pregnant women and the
aged in both developed and developing countries. The chal-
lenge of increased physiological requirements of Fe for growth
and reproduction, within these population groups is com-
pounded by inadequate intake and poor Fe bioavailability from
foods(2). This is particularly evident in populations subsisting
predominantly on vegetables or plants for their sources of Fe.
Substantive evidence has shown that IDA has debilitating
effects on cognition, mental function, work performance and
pregnancy outcomes(3,4). Consequently, Fe supplementation
and fortiﬁcation of staple foods in different countries(5) have
been practical approaches to alleviate this important nutritional
disorder. Fe compounds used for such purposes include ferrous
sulphate, ferric pyrophosphate, fumarate, gluconate and ferric
ammonium citrate among a host of others. Some of these Fe
formulations, because they are redox active, cause irritations or
disturbances to the gastrointestinal tract by inducing stomach
upset, abdominal pain, constipation or nausea(6–8). Fe supple-
ments, as a locus of high concentration of Fe in the gastro-
intestinal lumen, could cause DNA damage by generating
reactive oxygen species in Fenton reaction. Strategies and
initiatives aimed at ameliorating some of the adverse effects of
Fe supplements led to the synthesis of nano Fe compounds
such as a nano particulate ligand modiﬁed Fe(III) polyoxo-
hydroxide(9) and nanoparticulate Fe pyrophosphates(7), which
were shown to have high bioavailability. This promising
outcome underlines the need to exploit and explore other
formulations or compounds that exhibit rigid chemical
structures, are redox inert, and are highly soluble to maintain
colloidal Fe for absorption in the milieu of the gastrointestinal
tract. Consequently, Fe multi-amino acid chelate (IMAAC) was
formulated and found to be better tolerated than FeSO4 in a
randomised, double-blind placebo-controlled trial (RCT) in
healthy premenstrual women(10). There is currently no infor-
mation on the metabolism and the mechanism of Fe absorption
from IMAAC. The present study, therefore, investigates the
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bioavailability, characteristics and metabolism of IMAAC using
both in vitro cell culture and in vivo mice models. It is hypo-
thesised that Fe absorption from IMAAC will be comparable
with that of standard FeSO4. To test this hypothesis, anaemic
mice were administered IMAAC or FeSO4 to evaluate Hb
regeneration, serum, liver and spleen Fe levels and Fe-related
genes in the tissues.
Methods
Reagents and chemicals
Unless otherwise stated chemicals and reagents were obtained
from Sigma-Aldrich. Standard American Institute of Nutrition
diet (AIN-76A) without Fe (low-Fe diet) and the Fe-replete diet
contained 48mg/kg Fe were provided to the mice. IMAAC was
prepared and supplied by Biotron Laboratories, Centerville UT,
USA. IMAAC used contained 10% elemental Fe chelated in an
aqueous solution to low molecular weight peptides, polypep-
tides and amino acids derived from enzymatically hydrolysed
soya protein isolates using non-GM organism Food chemical
codex/food grade enzymes. The preparation is then dried and
milled to a ﬁne powder. IMAAC preparation with excipients
was used in a RCT to test safety and tolerability(10).
Animal studies
Three-week-old CD1 strain male mice (Charles Rivers) were
used for the studies. Mice were housed in a light- and a
temperature-controlled room with ad libitum access to diet and
water. Fe-deﬁcient diet (TD 80396, 3/kg Fe, and Fe-replete diet
TD 80396, 48mg/kg ferric citrate (Harlan Teklad) were used for
the experiment and the diets composition, a modiﬁcation of
AIN-76A is given by Chaudhury et al.(11).
Hb repletion study
In all, ﬁfteen CD1 mice were made Fe deﬁcient on a low Fe diet
of 3mg/kg, for 3 weeks. Five mice were also placed on a
normal Fe-replete diet (48mg/kg) to serve as a control. Fol-
lowing this, blood was withdrawn from the tails to determine
the initial Hb levels of the mice. The Fe-depleted mice were
then divided into three treatment groups based on similar Hb
levels. These ﬁfteen mice were maintained on the low-Fe diet in
groups of ﬁve, of which one group did not receive any Fe
supplementation (low-Fe diet), the two other groups were
gavaged daily liquid solutions of 150 µg of Fe as IMAAC or
FeSO4. This was done for 10 d, and the total food consumption
of the mice was measured. After 10 d of Fe supplementation,
the mice were weighed, anaesthetised and blood samples were
taken for Hb and serum Fe determinations. The mice were then
killed, and the spleen, duodenum, kidney and liver samples
were excised, snap frozen in liquid N2 and stored in −80°C for
further analysis. The experiment was approved by the Institu-
tional (King’s College London) Animal Welfare and Ethics
Board. All procedures were approved and conducted in
accordance with the UK Animals (Scientiﬁc Procedures)
Act, 1986.
Measurement of Hb, serum iron and tissue non-haem
Fe contents
Hb concentrations were calculated from the change in optical
density at 540 nm, following the addition of 5 µl of whole blood
to Drabkin’s reagent (Sigma-Aldrich) and centrifugation
(Heraeus Biofuge Pico) at 13 000 rpm for 5min. Serum Fe was
measured with a liquid ferrozine-based Fe reagent (Thermo
Electron).
Tissue non-haem iron. Tissue samples were weighed and
homogenised (1:5, w/v) in 0·15 M-NaCl in 10mM-NaOH-Hepes
buffer (pH 7·0) using a 1ml glass Dounce homogenizer
(Wheaton Scientiﬁc). An aliquot of the homogenate was then
analysed for non-haem Fe content as described by Simpson &
Peters(12). The Fe values were expressed as either content (µmol
Fe/organ) or concentration (nmol Fe/mg wet weight).
Quantitative real-time reverse transcription PCR
Total RNA was extracted from tissue samples using TRIZOL
reagent (Invitrogen) according to manufacturer’s instructions.
Quantitative RT-PCR was carried out using an ABI Prism 7000
(Applied Biosystems) detection system in a two-step protocol
with Roche Universal primers and probes. Quantitative mea-
surement of each gene was normalised to the cycle threshold
value for ribosomal protein L (ribosomal protein L19 (RPL 19)).
Sequences of mouse primers used, forward and reverse,
respectively, are as follows:
Dcytb forward GTGACCGGCTTCGTCTTC
Dcytb reverse TGGATGGATTTCATCAAGAGC
Hepcidin forward AGAAAGCAGGGCAGACATTG
Hepcidin reverse CACTGGGAATTGTTACAGCATT
DMT1 forward CACCGTCAGTATCCCAAGGT
DMT1 reverse CCAATGATTGCCAACTCCA
Ferroportin forward TTGTTGTTGTGGCAGGAGAA
Ferroportin reverse AGCTGGTCAATCCTTCTAATGG
RPL 19 forward CTCGTTGCCGGAAAAACA
RPL 19 reverse TCATCCAGGTCACCTTCTCA
Cell studies
Duodenal HuTu 80 cells were obtained from the American
Type Culture Collection. Cells were cultured in Dulbecco’s
Modiﬁed Eagle Medium (DMEM; Life TechnologiesTM) supple-
mented with 10% fetal calf serum (Sigma-Aldrich) and with
100 kU/l of penicillin and 100mg/l streptomycin. Cells were
maintained at 37°C in an atmosphere of 5% CO2 and 95% air at
a relative humidity of approximately 95%. Cells were passaged
at 70% conﬂuence using Gibco® Versene Solution (Life
TechnologiesTM).
Iron uptake. A balanced salt solution (BSS) containing 130mM-
NaCl, 10mM-KCl, 1mM-MgSO4, 5mM-glucose and 1·8mM-CaCl2
in 10mM-piperazine-N,N ′-bis(2-ethanesulfonic acid) buffer (pH
6·5) that was reported to prevent precipitation or aggregation of
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nano-Fe(III), Fe compound was used for cell uptake studies(13).
Unless otherwise stated the Fe concentration was 10 µm. Con-
ﬂuent HuTu 80 cells were exposed to serum-free DMEM for 4 h
before Fe uptake studies. The cells were washed with pre-
warmed PBS before incubation with the different Fe com-
pounds or the non-supplemented BSS control for 1 h at 37°C.
After the Fe incubation period, the uptake medium was dec-
anted, and cells were washed three times with PBS–EDTA
(2mM) to remove Fe that bound non-speciﬁcally to the cell
membrane. Cells were suspended in fresh serum-free DMEM
and incubated for a further 23 h for ferritin synthesis. Following
this incubation period, cells were washed with PBS and lysed
with Mammalian Protein Extraction Reagent (Thermo Fisher
Scientiﬁc). The cell lysate was centrifuged (5min, 16 000 g) to
remove cell debris and the supernatant used for ferritin and
protein analysis.
Ferritin ELISA assay in cell lysates. The Spectro Ferritin MT
ELISA Kit (ATI Atlas) was used to determine cellular ferritin
content as described in the manufacturer’s protocol. Cellular
protein concentration was determined according to Bio-Rad
assay protocol (Bio-Rad Laboratories). Experiments were
carried out in triplicates, and data are expressed as ng ferritin
per mg protein.
Fe uptake and the effect of ferrous Fe inhibition were
determined in cells by co-incubating ferrozine (1mM) with
20 µM Fe from IMAAC and FeSO4 for 1 h. Following this, cells
were washed with versene (PBS–EDTA solution) and incubated
with serum-free DMEM for 23 h to allow ferritin synthesis.
Ferric reductase assay
Ferric reductase assay was performed on HuTu 80 cells plated
into twelve well plates. The cells were washed three times with
PBS, before incubation in a BSS buffer supplemented with either
IMAAC or ferric citrate (different concentrations) and 200 µM
3-(2-pyridyl)-5,6-diphenyl 1,2,4-triazine − 40 400-disulfonic acid
sodium salt (ferrozine). Ferric reduction of Fe was measured by
the formation of the coloured Fe(II)-ferrozine complex and
monitoring the change in absorbance at 562nm.
Statistical analysis
All values are expressed as means with their standard errors
from at least three different experiments. Statistical differences
between means were calculated using Student’s t test in
correcting for differences in sample variance. When multiple
comparisons were necessary, one-way or two-way ANOVA was
performed, using GraphPad with Tukey’s post hoc test. Differ-
ences were considered signiﬁcant at P< 0·05.
Results
In vivo bioavailability of Fe multi-amino acid chelate in
a mouse feeding study
There were no statistical differences (P> 0·05) in initial and
ﬁnal body weights between the experimental groups over the
intervention period (Table 1). Average feed intake was 71·76 g
and there were no differences between the groups (Table 1).
Fe intakes of mice expressed as mg/kg body weight are,
respectively, 0·62 (SD 0·02), 4·27 (SD 0·11), 4·54 (SD 0·17)
and 9·88 (SD 0·33) for Fe-deﬁcient, FeSO4, IMAAC and
Fe-replete diets.
Efﬁcacy of Hb repletion was employed to compare IMAAC
and FeSO4 following diet-induced Fe deﬁciency. Mice fed a diet
low in Fe (Fe-deﬁcient group) for 4 weeks showed signiﬁcantly
(P< 0·001) lower blood Hb levels than control mice kept on the
Fe-replete diet (Fe-replete group) throughout (Fig. 1(a)). Sup-
plementation of the Fe-deﬁcient diet with either IMAAC or
FeSO4 for 10-d signiﬁcantly increased Hb levels in comparison
with mice fed the Fe-deﬁcient diet throughout (P< 0·001 and
P< 0·005), respectively (Fig. 1(a)). Furthermore, Fig. 1(b) shows
that only supplemented mice had a signiﬁcant gain in Hb levels
from baseline. Moreover, serum Fe levels were signiﬁcantly
higher in the mice fed the Fe-replete diet (P< 0·005) or sup-
plemented Fe (P< 0·001) than the mice on the Fe deﬁcient diet
(Fig. 1(c)). There was no signiﬁcant difference in serum Fe
between mice, which were given FeSO4 or IMAAC supple-
mentation (P> 0·05).
Tissue non-haem iron of mice
Mice receiving Fe supplementation had signiﬁcantly higher liver
non-haem Fe levels (Fig. 2(a)) than the mice receiving the
Fe-replete diet (P< 0·005) and the Fe-deﬁcient diet (P< 0·001).
Mice on the control Fe-replete diet had signiﬁcantly higher liver
Fe levels that the Fe-deﬁcient group (P< 0·05) as expected.
There was no difference in liver levels of Fe between FeSO4 and
IMAAC supplementation (P> 0·05). Similarly, mice on Fe
replete or FeSO4 or IMAAC supplementation exhibited
signiﬁcantly higher (P< 0·001) splenic Fe levels than mice fed
Table 1. Initial and final body weights and feed intake of the experimental groups*
(Mean values and standard deviations, n 5)
Fe-replete Fe-deficient FeSO4 IMAAC
Groups Mean SD Mean SD Mean SD Mean SD
Initial body weight (g) 34·04 1·9 32·17 2·4 34·19 2·3 32·60 2·8
Final body weight (g) 34·85 2·7 33·74 1·9 35·24 2·0 33·27 3·0
Feed intake (g)/10 d 71·38 0·8 71·43 1·5 72·45 1·6 71·78 0·9
IMAAC, Fe multi-amino acid chelate.
* Data were analysed by two-way ANOVA followed by the Tukey’s post hoc test. There were no significant differences in the parameters between the groups.
Bioavailability of iron multi-amino acid chelate 769
https://doi.org/10.1017/S0007114517000186
Downloaded from https://www.cambridge.org/core. King's College London, on 10 Dec 2018 at 09:09:56, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
Fe-deﬁcient diet (Fig. 2(b)). As shown in Fig. 2(c), although the
duodenal Fe levels increased in mice fed FeSO4 or IMAAC
supplements, the difference only reached signiﬁcance level
(P< 0·05) in the mice on the replete Fe diet compared with
mice on the Fe-deﬁcient diet. This trend is similar to the
observation in the kidney as shown in Fig. 2(d).
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Fig. 2. Intragastric administration of iron multi-amino acid chelate (IMAAC) or FeSO4 and tissue iron distribution of anaemic mice. Non-haem iron levels in the liver (a),
spleen (b) duodenum (c) and kidney (d) of male CD1 mice following 10-d feeding with different test diets. Iron-replete ( ) control diet contained 48mg Fe/kg diet; the
iron-deficient ( ) diet contained approximately 3mg Fe/kg diet. Mice were maintained on the Fe-deficient diet and were supplemented daily by oral gavage with 150 µg
Fe as IMAAC ( ) or FeSO4 ( ). Values are means (n 5), with their standard errors. * P< 0·05, ** P< 0·01, *** P< 0·001.
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Fig. 1. Intragastric administration of iron multi-amino acid chelate (IMAAC) or FeSO4 and haematic responses of anaemic mice. Hb levels of male CD1 mice following
10-d of administering the test diets (a), Hb gains (b) and serum iron levels in the mice (c). Iron-replete ( ) control diet contained 48mg Fe/kg diet; the iron-deficient ( )
diet contained approximately 3mg Fe/kg diet. Mice were maintained on the iron-deficient diet and were supplemented daily by oral gavage with 150 µg Fe as
IMAAC ( ) or FeSO4 ( ). Values are means (n 5), with their standard errors. * P< 0·05, ** P< 0·01, *** P< 0·001.
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Gene expression in the duodenum and liver tissues of mice
As expected Fig. 3(a) indicates that hepcidin mRNA expression
in the liver was up-regulated signiﬁcantly in animals fed Fe
replete and supplemented Fe and signiﬁcantly down-regulated
in animals on the Fe-deﬁcient diet (P< 0·001). Consequently,
duodenal cytochrome b (Dcytb) mRNA levels (Fig. 3(b))
increased in the duodenum of the mice were given the
Fe-deﬁcient diet. Moreover, a trend of increase was observed in
the duodenal levels of divalent metal transporter 1 (DMT1) and
Fpn mRNA of Fe-deﬁcient mice (Fig. 3(c) and (d)). Fe supple-
mentation, however, signiﬁcantly (P< 0·01) down-regulated
Dcytb mRNA levels in the duodenum of mice. Down-regulation
of Fe transport genes was more responsive to FeSO4 than
IMAAC administration (Fig. 3(c) and (d)).
In vivo iron uptake and ferric iron reduction studies in HuTu
80 cells
Consistent with the observation in the in vivo mouse studies,
IMAAC and FeSO4 exhibited comparable Fe uptake values in
HuTu 80 cells (Fig. 4(a)). However, Fe(II) chelator ferrozine,
signiﬁcantly inhibited Fe uptake and utilisation from FeSO4
(P< 0·05), the effect on IMAAC was not signiﬁcant (Fig. 4(b)).
Ferric citrate reduction in HuTu 80 cells exhibited pH-
dependent activity that is higher than that of IMAAC (Fig. 4(c)
and (d)). Reductase activity was signiﬁcantly different
(P< 0·001) between pH 3·5 and 7·4 for both ferric citrate and
IMAAC. However, reduction of Fe and dissolution in the pre-
sence of ascorbic acid was higher with IMAAC (Fig. 4(c) and
(d)). Ascorbic acid signiﬁcantly enhanced (P< 0·01) ferric
reduction in both Fe compounds.
Discussion
Fe supplementation and food fortiﬁcation are panaceas aimed
at improving Fe nutrition(14,15) particularly to the vulnerable
groups of the population. These strategies, however, are asso-
ciated with diverse issues limiting effectiveness and as such are
subjects of continuing research and investigations. FeSO4, the
standard Fe supplement is highly reactive, potentially toxic and
prone to causing gastrointestinal disturbances. Alternatives such
as IMAAC was reported to be better tolerated than FeSO4 in a
RCT in healthy premenstrual women(10). The bioavailability,
metabolism and the mechanism of Fe absorption from IMAAC
were consequently investigated in Fe-deﬁcient mice in the
present study. In general, studies in humans revealed that dif-
ferences in diets that vary in bioavailability are apparent in
Fe-deﬁcient rather than in Fe-replete subjects(16).
The data demonstrate the comparable efﬁciency of both
IMAAC and ferrous sulphate in replenishing Hb in Fe-deﬁcient
mice and similar Fe uptake in vitro in intestinal HuTu 80 cells.
This agrees with the observation of which Fe glycine chelate
compared with FeSO4 in Hb repletion of chicks
(17) and in a study
that examines ferrous carbamoyl glycine with FeSO4 in rats
(18).
Furthermore, Fe glycine chelate was equally efﬁcacious in treating
cancer patients with mild IDA(19). Remarkably, however, IMAAC
is a repository of Fe and several amino acids. Consequently, tol-
erability of IMAAC possibly accrues from combined antioxidant
properties of the constituent multiple amino acids(20).
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Fig. 3. Intragastric administration of iron multi-amino acid chelate (IMAAC) or FeSO4 and mRNA levels of iron metabolism genes of anaemic mice. Hepcidin mRNA levels
in the liver (a) of male CD1 mice following 10-d feeding with different test diets as described above. DcytbmRNA expression (b), DMT1 (c) and ferroportin (Fpn) (d) levels in
the duodenum of mice on experimental diets. , iron replete; , iron deficient; , FeSO4; , IMAAC. * P<0·05, ** P<0·01, *** P<0·001.
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The study next compared the metabolism of Fe in IMAAC
with FeSO4 in mice. During Fe deﬁciency, liver and spleen Fe
stores are rapidly depleted to maintain Fe homoeostasis and
functional Fe requirements. Consequently, repletion of these
tissues during Fe supplementation is a relative marker of
bioavailability. IMAAC and FeSO4 supplementation had
equivalent levels of liver Fe repletion (Fig. 2(a)) compared with
the Fe-deﬁcient diet (P< 0·001). Furthermore, in the spleen
(Fig. 2(b)) the level of non-haem Fe was higher in the mice
given IMAAC (P< 0·005) than FeSO4 compared with the
Fe-deﬁcient diet. In fact, FeSO4 caused a similar level of splenic
non-haem Fe to the Fe-replete diet. The spleen is the last tissue
in the body to replenish its Fe stores after Fe deﬁciency(21). This
observation was also evident in pregnant pigs that were given
hydrolysed soya protein Fe AAC supplement for 4 weeks before
parturition. On analysis, there was 34·5% greater non-haem
Fe levels in the liver and 8·5% higher Fe in the spleen of piglets
whose mothers were given the Fe amino acid chelate supple-
ment compared with the control group(22). In addition to tissue
Fe, IMAAC modulation of Fe metabolism genes in mice was also
evident in the present study.
Remarkably, though, administration of IMAAC supplement for
10d replenished Fe stores of anaemic mice to the same level as
the normal healthy mice kept on the Fe replete diet despite sig-
niﬁcant difference (P< 0·001) in Fe intake (4·54 (SD 0·17) v. 9·88
(SD 0·33)mg/kg body weight). Fe intake (4·27 (SD 0·11)mg/kg
body weight) of mice that were given FeSO4 was comparable
with those on IMAAC. This attests to the superior Fe bioavail-
ability of IMAAC and FeSO4 than ferric citrate Fe component of
the Fe-replete diet (TD 80396, 48mg/kg ferric citrate (Harlan
Teklad). Contrary to some concerns(23) that Fe chelates if absor-
bed intact could bypass the normal homoeostatic regulatory
mechanisms, Fe amino acid chelates were reported to be regu-
lated by the body’s Fe status in humans(24). Expression of hep-
cidin and other Fe metabolism genes were mostly appropriately
modulated by IMAAC and FeSO4 supplementation in the present
study. As expected from gene expression studies, hepcidinmRNA
levels (Fig. 3(a)) was down-regulated in mice given the
Fe-deﬁcient diet and up-regulated by both Fe supplements
(P< 0·005). Consequently, DMT1, ferroportin and, in particular,
Dcytb mRNA levels (Fig. 3(b)–(d)) were up-regulated in mice on
the Fe-deﬁcient diet and down-regulated in both groups on
supplements (P< 0·001). These results reﬂect the effectiveness of
both Fe supplements in resolving IDA. Furthermore, increased
hepcidin expression will exert a negative feedback regulation of
the genes involved in Fe transport machinery until Fe homo-
eostasis is restored. Hb repletion and hepatic hepcidin mRNA
levels exhibited a trend that reﬂected responsiveness to bioa-
vailability of IMAAC and FeSO4 in mice (Figs. 1(a) and 3(a)). This
might be similar to the luminal endocytic uptake of nanoparti-
culate Fe(3+) poly oxo-hydroxide (nanoFe(3+)), which differs from
the uptake mechanism of inorganic ferrous ion(9), but both share
a ferroportin-dependent abluminal efﬂux mechanism into the
circulation(25). This is consistent with the concept of the labile Fe
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Fig. 4. Iron uptake and in vitro solubilisation of iron multi-amino acid chelate (IMAAC) in HuTu 80 cells. Cellular ferritin levels in HuTu 80 cells (a) after a 1-h exposure to
50 µm (Fe) as IMAAC, ferrous sulphate (FeSO4) or co-incubation with ferrozine (1mm) (b). Effect of varying pH and on reductive iron dissolution from IMAAC (c) or
ferric citrate (d). HuTu 80 cells were exposed to 50 µm (Fe) as IMAAC, FeSO4 in balanced salt solution following which (Fe(II) was measured using ferrozine. Total
reducible iron was subsequently determined by the addition of ascorbic acid (1mm). Values are means, and standard deviations of three independent experiments with
three replicate wells per experiment. , Untreated cells; , IMAAC; , IMAAC+ ferrozine; , FeSO4; , FeSO4 + ferrozine; , IMAAC; , IMAAC+ascorbic acid;
, ferric citrate; , ferric citrate + ascorbic acid.
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pool(26) in the cytosol, where Fe is released from inorganic or
organic complexes into the common matrix for efﬂux into
circulation as regulated by ferroportin/hepcidin interaction.
The chemical nature of IMAAC and the mechanism of the
Fe uptake process were studied in duodenal HuTu 80 cells
(Fig. 4(a)). The data suggest that the content of ferrous
chelatable Fe is more negligible in IMAAC than FeSO4 (Fig. 4
(b)). Food Fe sources and Fe salts are liable to autoxidation to
the ferric form as they traverse the neutral pH section of the
gastrointestinal tract. Consequently, the rate of dissolution of
Fe in different formulations(27) is critical in the absorption
efﬁciency. We next investigated the reductive dissolution of
IMAAC in the presence of ascorbic acid and compared this to
ferric citrate. While ferric citrate exhibited a pH-dependent
reductive dissolution of Fe (Fig. 4(c) and (d)), the dissolution of
IMAAC seems independent of pH. Ferrozine chelable Fe was
higher for FeSO4 than that of IMAAC, thus implying the avail-
ability of less redox active species in the later. This perhaps
explains the reported higher tolerability of IMAAC over FeSO4
in a RCT in human subjects(10). However, negligible free ferric
Fe component of IMAAC could be easily reduced by ascorbic
acid (Fig. 4(c)). Chelation, sequestration and encapsulation of
Fe by amino acids and peptides possibly prevent redox reac-
tivity in the lumen of the gastrointestinal tract. For inorganic
Fe salts, however, the rate of autoxidation and dissolution of the
ferric Fe in different formulations(27) could be critical in the
absorption efﬁciency in the proximal duodenal tract. However,
the resultant consequences on microbial population and the
generation of reactive Fe species in the distal duodenum are
subject of continuing investigation(28).
IMAAC has been shown to compare favourably well with
FeSO4 in Hb regeneration of anaemic mice and in vitro
HuTu 80 intestinal Fe uptake studies. It has potential, therefore,
to be used widely as an alternative to FeSO4 in the management
of IDA as it has been shown to be better tolerated than FeSO4 in
humans. In vitro cell culture studies offer opportunities for
screening Fe compounds such as pyrophosphate, gluconate,
ammonium citrate and bis glycinate, etc. as the relative stability
of various Fe compounds in vivo has been a matter of uncer-
tainty to the nutrition industry. On the other hand, animal
studies may be useful for evaluating relative bioavailability and
understanding the mechanisms of Fe absorption; the results
may not wholly translate to what occurs in humans and inter-
pretations as such should be treated with caution(29). Future
studies on IMAAC could be for a longer duration to investigate
the balance of the highly bioavailable Fe species and the
potentials of pathogenic microbes to pilfer this Fe source for
proliferation in the lower segment of the gastrointestinal tract.
Fe absorption in mice and cells was comparable for both
IMAAC and FeSO4 and both compounds induced and regulated
Fe metabolism genes in a similar way.
Acknowledgements
G. O. L.-D. acknowledges funding support of the Diabetes and
Nutritional Sciences Division, King’s College London. The
IMAAC supplement called FerriActiv was prepared by Biotron
Laboratories, Centerville, USA. The authors are grateful to Dr
Gameil Fouad for providing IMAAC supplement.
G. O. L -D. designed and conducted the research, analysed the
data and wrote the manuscript; N. K., C. B., A. C. and G. T.
performed the experiments, data collection and statistical analysis.
All authors declare that they have no conﬂicts of interest.
References
1. World Health Organization (2014) Micronutrient deﬁciencies –
iron deﬁciency anaemia. http://www.who.int/nutrition/
topics/ida/en/# (accessed November 2014).
2. Aspuru K, Villa C, Bermejo F, et al. (2011) Optimal manage-
ment of iron deﬁciency anemia due to poor dietary intake. Int
J Gen Med 4, 741–750.
3. Munoz P & Humeres A (2012) Iron deﬁciency on neuronal
function. Biometals 25, 825–835.
4. Rufer ES, Tran TD, Attridge MM, et al. (2012) Adequacy of
maternal iron status protects against behavioral, neuroanato-
mical, and growth deﬁcits in fetal alcohol spectrum disorders.
PLoS ONE 7, e47499.
5. Gera T, Sachdev HS & Boy E (2012) Effect of iron-fortiﬁed
foods on hematologic and biological outcomes: systematic
review of randomized controlled trials. Am J Clin Nutr 96,
309–324.
6. Tiwari AK, Mahdi AA, Chandyan S, et al. (2011) Oral iron
supplementation leads to oxidative imbalance in anemic
women: a prospective study. Clin Nutr 30, 188–193.
7. Hilty FM, Arnold M, Hilbe M, et al. (2010) Iron from
nanocompounds containing iron and zinc is highly bioavail-
able in rats without tissue accumulation. Nat Nanotechnol 5,
374–380.
8. Tolkien Z, Stecher L, Mander AP, et al. (2015) Ferrous sulfate
supplementation causes signiﬁcant gastrointestinal side-effects
in adults: a systematic review and meta-analysis. PLOS ONE
10, e0117383.
9. Pereira DI, Bruggraber SF, Faria N, et al. (2014) Nanoparti-
culate iron(III) oxo-hydroxide delivers safe iron that is
well absorbed and utilised in humans. Nanomedicine 10,
1877–1886.
10. Fouad GT, Evans M, Sharma P, et al. (2013) A randomized,
double-blind clinical study on the safety and tolerability of an
iron multi-amino acid chelate preparation in premenopausal
women. J Diet Suppl 10, 17–28.
11. Chaudhury C, Kim J, Mehnaz S, et al. (2006) Accelerated
transferrin degradation in HFE-deﬁcient mice is associated
with increased transferrin saturation. J Nutr 136, 2993–2998.
12. Simpson RJ & Peters TJ (1990) Forms of soluble iron in mouse
stomach and duodenal lumen: signiﬁcance for
mucosal uptake. Br J Nutr 63, 79–89.
13. Pereira DI, Mergler BI, Faria N, et al. (2013) Caco-2 cell
acquisition of dietary iron(III) invokes a nanoparticulate
endocytic pathway. PLOS ONE 8, e81250.
14. Prentice AM, Mendoza YA, Pereira D, et al. (2017) Dietary
strategies for improving iron status: balancing safety and
efﬁcacy. Nutr Rev 75, 49–60.
15. Latunde-Dada GO, Pereira DI, Tempest B, et al. (2014)
A nanoparticulate ferritin-core mimetic is well taken up by
HuTu 80 duodenal cells and its absorption in mice is regulated
by body iron. J Nutr 144, 1896–1902.
16. Hulten L, Gramatkovski E, Gleerup A, et al. (1995)
Iron absorption from the whole diet. Relation to meal com-
position, iron requirements and iron stores. Eur J Clin Nutr
49, 794–808.
Bioavailability of iron multi-amino acid chelate 773
https://doi.org/10.1017/S0007114517000186
Downloaded from https://www.cambridge.org/core. King's College London, on 10 Dec 2018 at 09:09:56, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
17. Ma WQ, Sun H, Zhou Y, et al. (2012) Effects of iron glycine
chelate on growth, tissue mineral concentrations, fecal
mineral excretion, and liver antioxidant enzyme activities in
broilers. Biol Trace Elem Res 149, 204–211.
18. Zhang Y, Sun X, Xie C, et al. (2015) Effects of ferrous carba-
moyl glycine on iron state and absorption in an iron-deﬁcient
rat model. Genes Nutr 10, 54.
19. Ferrari P, Nicolini A, Manca ML, et al. (2012) Treatment of mild
non-chemotherapy-induced iron deﬁciency anemia in cancer
patients: comparison between oral ferrous bisglycinate chelate
and ferrous sulfate. Biomed Pharmacother 66, 414–418.
20. Elias RJ, Bridgewater JD, Vachet RW, et al. (2006) Antioxidant
mechanisms of enzymatic hydrolysates of beta-lactoglobulin
in food lipid dispersions. J Agric Food Chem 54, 9565–9572.
21. Chua-anusorn W, Webb J, Macey DJ, et al. (1999) The effect of
prolonged iron loading on the chemical form of iron oxide
deposits in rat liver and spleen. Biochim Biophys Acta 1454,
191–200.
22. Brady PS, Ku PK, Ullrey DE, et al. (1978) Evaluation of an
amino acid-iron chelate hematinic for the baby pig. J Anim Sci
47, 1135–1140.
23. Allen LH (2002) Advantages and limitations of iron
amino acid chelates as iron fortiﬁcants. Nutr Rev 60,
S18–S21.
24. Olivares M, Pizarro F, Pineda O, et al. (1997) Milk inhibits and
ascorbic acid favors ferrous bis-glycine chelate bioavailability
in humans. J Nutr 127, 1407–1411.
25. Aslam MF, Frazer DM, Faria N, et al. (2014) Ferroportin
mediates the intestinal absorption of iron from a
nanoparticulate ferritin core mimetic in mice. FASEB J 28,
3671–3678.
26. Jacobs A (1977) Low molecular weight intracellular iron
transport compounds. Blood 50, 433–439.
27. Harju E (1989) Clinical pharmacokinetics of iron preparations.
Clin Pharmacokinet 17, 69–89.
28. Pereira DI, Aslam MF, Frazer DM, et al. (2015) Dietary iron
depletion at weaning imprints low microbiome diversity and
this is not recovered with oral Nano Fe(III). Microbiologyopen
4, 12–27.
29. Reddy MB & Cook JD (1991) Assessment of dietary
determinants of nonheme-iron absorption in humans and rats.
Am J Clin Nutr 54, 723–728.
774 N. Kajarabille et al.
https://doi.org/10.1017/S0007114517000186
Downloaded from https://www.cambridge.org/core. King's College London, on 10 Dec 2018 at 09:09:56, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
